Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3190)
All Articles published online
|
Jul 28, 2011 (publication date) through Oct 17, 2019
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Number | Cited Articles |
| 1 |
Kristian Aarslev, Anders Dige, Stinne R. Greisen, Martin Kreutzfeldt, Niels Jessen, Hendrik Vilstrup, Bent Deleuran, Henning Grønbæk. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. Scandinavian Journal of Gastroenterology 2017; 52(1): 93 doi: 10.1080/00365521.2016.1233576
|
| 2 |
Valli De Re, Maria Lina Tornesello, Mariangela De Zorzi, Laura Caggiari, Francesca Pezzuto, Patrizia Leone, Vito Racanelli, Gianfranco Lauletta, Laura Gragnani, Angela Buonadonna, Emanuela Vaccher, Anna Linda Zignego, Agostino Steffan, Franco M. Buonaguro. Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma. Frontiers in Microbiology 2019; 10 doi: 10.3389/fmicb.2019.00475
|
| 3 |
Mercedes Iñarrairaegui, Delia D’Avola, Bruno Sangro. Immunotherapy of Hepatocellular Carcinoma. 2017; : 51 doi: 10.1007/978-3-319-64958-0_4
|
| 4 |
Naofumi Mukaida, Yasunari Nakamoto. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. World Journal of Gastroenterology 2018; 24(17): 1839-1858 doi: 10.3748/wjg.v24.i17.1839
|
| 5 |
Fabian Finkelmeier, Özge Canli, Andrea Tal, Thomas Pleli, Jörg Trojan, Michael Schmidt, Bernd Kronenberger, Stefan Zeuzem, Albrecht Piiper, Florian R. Greten, Oliver Waidmann. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. European Journal of Cancer 2016; 59: 152 doi: 10.1016/j.ejca.2016.03.002
|
| 6 |
Christopher E Jensen, Arturo Loaiza-Bonilla, Paula A Bonilla-Reyes. Immune checkpoint inhibitors for hepatocellular carcinoma. Hepatic Oncology 2016; 3(3): 201 doi: 10.2217/hep-2016-0004
|
| 7 |
Carolina Boni, Valeria Barili, Greta Acerbi, Marzia Rossi, Andrea Vecchi, Diletta Laccabue, Amalia Penna, Gabriele Missale, Carlo Ferrari, Paola Fisicaro. HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. International Journal of Molecular Sciences 2019; 20(11): 2754 doi: 10.3390/ijms20112754
|
| 8 |
Colleen S. Curran, Elad Sharon. PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma. Seminars in Oncology 2017; 44(6): 428 doi: 10.1053/j.seminoncol.2017.12.001
|
| 9 |
Mariko Ishibashi, Hiromi Yamaguchi, Yukari Hirotani, Akihisa Sakurada, Toshihide Endo, Masahiko Sugitani, Tadatoshi Takayama, Makoto Makishima, Mariko Esumi. Contradictory intrahepatic immune responses activated in high-load hepatitis C virus livers compared with low-load livers. Archives of Virology 2018; 163(4): 855 doi: 10.1007/s00705-017-3675-8
|
| 10 |
Cheng-Piao Luo, Han-Yue Mo, Ling-Ling Wu, Yun Ma, Ning-Fu Peng. Soluble PD-L1 and prognosis of patients with hepatocellular carcinoma. European Journal of Cancer 2017; 71: 117 doi: 10.1016/j.ejca.2016.09.040
|
| 11 |
Maridi Aerts, Daphné Benteyn, Hans Van Vlierberghe, Kris Thielemans, Hendrik Reynaert. Current status and perspectives of immune-based therapies for hepatocellular carcinoma. World Journal of Gastroenterology 2016; 22(1): 253-261 doi: 10.3748/wjg.v22.i1.253
|
| 12 |
Tim F. Greten, Firouzeh Korangy. Immunotherapy of Hepatocellular Carcinoma. 2017; : 121 doi: 10.1007/978-3-319-64958-0_8
|
| 13 |
Scott Balsitis, Volodymyr Gali, Pamela J. Mason, Susan Chaniewski, Steven M. Levine, Michael J. Wichroski, Michael Feulner, Yunling Song, Karen Granaldi, James K. Loy, Chris M. Thompson, Jacob A. Lesniak, Catherine Brockus, Narendra Kishnani, Stephan Menne, Mark I. Cockett, Renuka Iyer, Stephen W. Mason, Daniel J. Tenney, Isabelle Chemin. Safety and efficacy of anti-PD-L1 therapy in the woodchuck model of HBV infection. PLOS ONE 2018; 13(2): e0190058 doi: 10.1371/journal.pone.0190058
|
| 14 |
Ming-fa Chen, Yong Lin, You-chen Xia, Chan Sun, Xue-mei Feng, Meng-ji Lu, Dong-liang Yang, Jun Wu. Establishment and application of hepatitis B virus persistent replication model in IFNAR−/− mouse. Journal of Huazhong University of Science and Technology [Medical Sciences] 2013; 33(3): 392 doi: 10.1007/s11596-013-1130-y
|
| 15 |
Weimin Zhu, Rui Bao, Xiaohua Fan, Tianzhu Tao, Jiali Zhu, Jiafeng Wang, Jinbao Li, Lulong Bo, Xiaoming Deng. PD-L1 Blockade Attenuated Sepsis-Induced Liver Injury in a Mouse Cecal Ligation and Puncture Model. Mediators of Inflammation 2013; 2013: 1 doi: 10.1155/2013/361501
|
| 16 |
Michael J. Flynn, Anwar A. Sayed, Rohini Sharma, Abdul Siddique, David J. Pinato. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Hepatology 2019; 69(5): 2258 doi: 10.1002/hep.30337
|
| 17 |
Elisabetta Cariani, Gabriele Missale. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications. Liver International 2019; 39(9): 1608 doi: 10.1111/liv.14192
|
| 18 |
Changhoon Choi, Gyu Sang Yoo, Won Kyung Cho, Hee Chul Park. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World Journal of Gastroenterology 2019; 25(20): 2416-2429 doi: 10.3748/wjg.v25.i20.2416
|
| 19 |
Fanzhi Meng, Shoumei Zhen, Bin Song. HBV-specific CD4+ cytotoxic T cells in hepatocellular carcinoma are less cytolytic toward tumor cells and suppress CD8+ T cell-mediated antitumor immunity. APMIS 2017; 125(8): 743 doi: 10.1111/apm.12704
|
| 20 |
Noelle A. Hutchins, Fei Wang, Yvonne Wang, Chun-Shiang Chung, Alfred Ayala. Kupffer cells potentiate liver sinusoidal endothelial cell injury in sepsis by ligating programmed cell death ligand-1. Journal of Leukocyte Biology 2013; 94(5): 963 doi: 10.1189/jlb.0113051
|
| 21 |
Xianjing Li, Zhuo Wang, Yulian Zou, Ermei Lu, Jingjing Duan, Hongbao Yang, Qijin Wu, Xiaona Zhao, Yun Wang, Linjun You, Ling He, Tao Xi, Yong Yang. Pretreatment with lipopolysaccharide attenuates diethylnitrosamine-caused liver injury in mice via TLR4-dependent induction of Kupffer cell M2 polarization. Immunologic Research 2015; 62(2): 137 doi: 10.1007/s12026-015-8644-2
|
| 22 |
Sehar Afreen, Said Dermime. The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. Hematology/Oncology and Stem Cell Therapy 2014; 7(1): 1 doi: 10.1016/j.hemonc.2013.09.005
|
| 23 |
Tai Hato, Lipika Goyal, Tim F. Greten, Dan G. Duda, Andrew X. Zhu. Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. Hepatology 2014; 60(5): 1776 doi: 10.1002/hep.27246
|
| 24 |
Omneya Y. Bassyoni, Heba M. Rashad. Expression of PD-1/PD-L1 and P53 in hepatocellular carcinoma. Egyptian Journal of Pathology 2018; 38(1): 131 doi: 10.1097/01.XEJ.0000542236.83764.02
|
| 25 |
Zuzana Macek Jilkova, Caroline Aspord, Keerthi Kurma, Anouck Granon, Christian Sengel, Nathalie Sturm, Patrice N. Marche, Thomas Decaens. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. Clinical and Translational Gastroenterology 2019; 10(7): e00058 doi: 10.14309/ctg.0000000000000058
|
| 26 |
Stephen A. Locarnini, Michael Roggendorf. Viral Hepatitis. 2013; : 96 doi: 10.1002/9781118637272.ch7
|
| 27 |
Yaron Ilan. Immune therapy for hepatocellular carcinoma. Hepatology International 2014; 8(S2): 499 doi: 10.1007/s12072-013-9501-9
|
| 28 |
|
| 29 |
Zhu Li, Na Li, Fang Li, Zhihua Zhou, Jiao Sang, Yanping Chen, Qunying Han, Yi Lv, Zhengwen Liu. Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma. Medicine 2016; 95(52): e5749 doi: 10.1097/MD.0000000000005749
|
| 30 |
Hazel Lote, Catherine Cafferkey, Ian Chau. PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treatment Reviews 2015; 41(10): 893 doi: 10.1016/j.ctrv.2015.09.004
|
| 31 |
Junsik Park, Minsuk Kwon, Eui-Cheol Shin. Immune checkpoint inhibitors for cancer treatment. Archives of Pharmacal Research 2016; 39(11): 1577 doi: 10.1007/s12272-016-0850-5
|
| 32 |
Zuzana Macek Jilkova, Caroline Aspord, Thomas Decaens. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. Cancers 2019; 11(10): 1554 doi: 10.3390/cancers11101554
|
| 33 |
G Lin, W Zhuang, X H Chen, C Huang, X D Lin, Y J Huang, C Li. Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B. Annals of Oncology 2018; 29(2): 516 doi: 10.1093/annonc/mdx694
|
| 34 |
Oxana V. Makarova-Rusher, José Medina-Echeverz, Austin G. Duffy, Tim F. Greten. The yin and yang of evasion and immune activation in HCC. Journal of Hepatology 2015; 62(6): 1420 doi: 10.1016/j.jhep.2015.02.038
|
| 35 |
Zongwen Shuai, Miranda WY Leung, Xiaosong He, Weici Zhang, Guoxiang Yang, Patrick SC Leung, M Eric Gershwin. Adaptive immunity in the liver. Cellular & Molecular Immunology 2016; 13(3): 354 doi: 10.1038/cmi.2016.4
|
| 36 |
Tim F. Greten, Bruno Sangro. Targets for immunotherapy of liver cancer. Journal of Hepatology 2018; 68(1): 157 doi: 10.1016/j.jhep.2017.09.007
|
| 37 |
Nobuhiro Tsuchiya, Yu Sawada, Itaru Endo, Yasushi Uemura, Tetsuya Nakatsura. Potentiality of immunotherapy against hepatocellular carcinoma. World Journal of Gastroenterology 2015; 21(36): 10314-10326 doi: 10.3748/wjg.v21.i36.10314
|
| 38 |
Antoine Hollebecque, David Malka, Charles Ferté, Michel Ducreux, Valérie Boige. Systemic treatment of advanced hepatocellular carcinoma: From disillusions to new horizons. European Journal of Cancer 2015; 51(3): 327 doi: 10.1016/j.ejca.2014.12.005
|
| 39 |
|
| 40 |
Christian Ihling, Bartholomew Naughton, Yue Zhang, P. Alexander Rolfe, Eveline Frick-Krieger, Luigi M. Terracciano, Isabelle Dussault. Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma. Frontiers in Medicine 2019; 6 doi: 10.3389/fmed.2019.00015
|
| 41 |
Ken Takahashi, Hiroyuki Marusawa. Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. Current Human Cell Research and Applications 2018; : 93 doi: 10.1007/978-981-10-6469-2_6
|
| 42 |
James J. Harding, Imane El Dika, Ghassan K. Abou-Alfa. Immunotherapy in hepatocellular carcinoma: Primed to make a difference?. Cancer 2016; 122(3): 367 doi: 10.1002/cncr.29769
|
| 43 |
Hae Il Jung, Dongjun Jeong, Sanghee Ji, Tae Sung Ahn, Sang Ho Bae, Susie Chin, Jun Chul Chung, Hyung Chul Kim, Moon Soo Lee, Moo-Jun Baek. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Cancer Research and Treatment 2017; 49(1): 246 doi: 10.4143/crt.2016.066
|
| 44 |
Smitha Menon, Sarah Shin, Grace Dy. Advances in Cancer Immunotherapy in Solid Tumors. Cancers 2016; 8(12): 106 doi: 10.3390/cancers8120106
|
| 45 |
Junyu Long, Jianzhen Lin, Anqiang Wang, Liangcai Wu, Yongchang Zheng, Xiaobo Yang, Xueshuai Wan, Haifeng Xu, Shuguang Chen, Haitao Zhao. PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy. Journal of Hematology & Oncology 2017; 10(1) doi: 10.1186/s13045-017-0511-2
|
| 46 |
Bruno Sangro, Daniel Palmer, Ignacio Melero. Immunotherapy of hepatocellular carcinoma. Hepatic Oncology 2014; 1(4): 433 doi: 10.2217/hep.14.16
|
| 47 |
Edward N. Harris, Justin L. Mott. Molecules, Systems and Signaling in Liver Injury. 2017; : 1 doi: 10.1007/978-3-319-58106-4_1
|
| 48 |
Yingxin Han, Hongmei Li, Yanfang Guan, Jian Huang. Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinoma. Cancer Letters 2016; 379(2): 206 doi: 10.1016/j.canlet.2015.06.022
|
| 49 |
Hao-Wen Sim, Jennifer Knox. Hepatocellular carcinoma in the era of immunotherapy. Current Problems in Cancer 2018; 42(1): 40 doi: 10.1016/j.currproblcancer.2017.10.007
|
| 50 |
Hui Li, Jun-Quan Xia, Fang-Shi Zhu, Zhao-Hong Xi, Cheng-Yu Pan, Li-Mei Gu, Yao-Zhou Tian. LPS promotes the expression of PD-L1 in gastric cancer cells through NF-κB activation. Journal of Cellular Biochemistry 2018; 119(12): 9997 doi: 10.1002/jcb.27329
|
| 51 |
Yu Akazawa, Toshihiro Suzuki, Toshiaki Yoshikawa, Shoichi Mizuno, Yasunari Nakamoto, Tetsuya Nakatsura. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-Analysis 2019; 7(3): 80-95 doi: 10.13105/wjma.v7.i3.80
Abstract(130) |
Core Tip(128) |
Full Article(HTML)(1032)
|
Full Article (PDF)-1765K(81)
|
Full Article (Word)-395K(31)
|
Audio-735K(8)
|
Peer-Review Report-163K(20)
|
Answering Reviewers-111K(14)
|
Times Cited (0)
|
Total Visits (1845)
|
Open
|
| 52 |
Elias A. Said, Iman Al-Reesi, Marwa Al-Riyami, Khalid Al-Naamani, Shadia Al-Sinawi, Mohammed S. Al-Balushi, Crystal Y. Koh, Juma Z. Al-Busaidi, Mohamed A. Idris, Ali A. Al-Jabri, Jean-Pierre Vartanian. Increased CD86 but Not CD80 and PD-L1 Expression on Liver CD68+ Cells during Chronic HBV Infection. PLOS ONE 2016; 11(6): e0158265 doi: 10.1371/journal.pone.0158265
|
| 53 |
Zhi-liang Wang, Guan-zhang Li, Qiang-wei Wang, Zhao-shi Bao, Zheng Wang, Chuan-bao Zhang, Tao Jiang. PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. OncoImmunology 2019; 8(2): e1541535 doi: 10.1080/2162402X.2018.1541535
|
| 54 |
Lina Quan, Xue Chen, Aichun Liu, Yan Zhang, Xiuchen Guo, Shujie Yan, Yue Liu, Luwen Zhang. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro. PLOS ONE 2015; 10(9): e0136476 doi: 10.1371/journal.pone.0136476
|
| 55 |
Ryan M. Hickey, Laura M. Kulik, Halla Nimeiri, Aparna Kalyan, Sheetal Kircher, Kush Desai, Ahsun Riaz, Robert J. Lewandowski, Riad Salem. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. Journal of Vascular and Interventional Radiology 2017; 28(11): 1487 doi: 10.1016/j.jvir.2017.07.018
|
| 56 |
Hao Qiu, Liang Zheng, Weifeng Tang, Pengfei Yin, Feng Cheng, Lixin Wang. Programmed death-1 (PD-1) polymorphisms in Chinese patients with esophageal cancer. Clinical Biochemistry 2014; 47(7-8): 612 doi: 10.1016/j.clinbiochem.2013.12.023
|
| 57 |
Thomas C Wirth. Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies. Expert Review of Gastroenterology & Hepatology 2014; 8(1): 101 doi: 10.1586/17474124.2014.862497
|
| 58 |
A. J. Robert McGray, Jonathan Bramson. Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. Advances in Experimental Medicine and Biology 2017; 1036: 213 doi: 10.1007/978-3-319-67577-0_14
|
| 59 |
Daniel L. Suzman, Lorraine Pelosof, Amy Rosenberg, Mark I. Avigan. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. Liver International 2018; 38(6): 976 doi: 10.1111/liv.13746
|
| 60 |
Feng Gao, Yang Zhang, Li-Kun Wang, Yong-Li Wei, Jing-Wei Wang, Cheng-Bao Wang, Qiang Li. A Meta-Analysis of the Correlation Between the HLA-DRB1*03 Allele and Chronic Hepatitis B in the Han Chinese Population. Genetic Testing and Molecular Biomarkers 2015; 19(4): 218 doi: 10.1089/gtmb.2014.0096
|
| 61 |
Rong-Miao Zhou, Yan Li, Na Wang, Xi Huang, Shi-Ru Cao, Bao-En Shan. Association of programmed death-1 polymorphisms with the risk and prognosis of esophageal squamous cell carcinoma. Cancer Genetics 2016; 209(9): 365 doi: 10.1016/j.cancergen.2016.06.006
|